**Supplemental** table 2**: Descriptive values of figure 1. A)** Neutrophil counts of wild-type and adenosine A2B receptor knockout animals in circulation, peritoneal lavage, liver, and lung tissue without respectively with zymosan administration and with zymosan and sevoflurane treatment. **B)** Myeloperoxidase and **C)** protein values at indicated conditions. **D)** Concentrations of keratinocyte-derived chemokine, macrophage-inflammatory protein-2, tumor necrosis factor α, and interleukin-6 in the peritoneal lavage were assessed at indicated conditions. Fecal-induced neutrophil accumulation in the **E)** lavage, **F)** liver, and **G)** lung tissue of wild-type animals were evaluated with and without sevoflurane treatment. **H)** Myeloperoxidase and **I)** protein concentration were detected in the lavage at indicated conditions. All statistic data presented as the mean ± SD or as the median and 25%/75% percentile. Statistical analyses were performed by one-way ANOVA + Bonferroni test and two-group analyses by unpaired *t*-tests or Mann-Whitney tests.

|  |  |  |
| --- | --- | --- |
| **Table 2A**  | **Neutrophils (x105)** | ***P* values; n counts** |
| Blood: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 0.7 ± 0.3 x105vs. 0.5 ± 0.2 x105 | P=0.021n=15/17 |
| Blood: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 0.5 ± 0.1 x105vs. 0.6 ± 0.2 x105 | P=nsn=13/13 |
| Lavage: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 25.2 ± 17.1 x105vs. 12.2 ± 6.9 x105 | P=0.004n=19/17 |
| Lavage: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 23.4 ± 10.0 x105vs. 20.8 ± 5.4 x105 | P=nsn=10/9 |
| Liver: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 18.8 ± 5.7 x105vs. 12.9 ± 6.9 x105 | P=0.031n=13/19 |
| Liver: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 20.0 ± 4.8 x105vs. 18.1 ± 7.1 x105 | P=nsn=17/13 |
| Lung: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 35.7 ± 16.4 x105vs. 23.9 ± 6.8 x105 | P=0.021n=14/12 |
| Lung: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 31.0 ± 12.1 x105vs. 28.7 ± 6.7 x105 | P=nsn=12/15 |

|  |  |  |
| --- | --- | --- |
| **Table 2B Myeloperoxidase** | **[405nm/ml]** | ***P* values; n counts** |
| Wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 9702 ± 4954vs. 5665 ± 1790 | P=0.040n=9/8 |
| Adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 8352 ± 2741vs. 8198 ± 2995 | P=nsn=8/9 |

|  |  |  |
| --- | --- | --- |
| **Table 2B Protein** | **[mg/ml]** | ***P* values; n counts** |
| Wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.4 ± 0.5vs. 0.8 ± 0.4 | P=0.002n=12/11 |
| Adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.4 ± 0.4vs. 1.2 ± 0.4 | P=nsn=12/10 |

|  |  |  |
| --- | --- | --- |
| **Table 2D Cytokines** | **[pg/ml]** | ***P* values; n counts** |
| Keratinocyte-derived chemokine: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 11090 ± 2287vs. 6263 ± 1986 | P<0.001n=9/10 |
| Keratinocyte-derived chemokine: adenosine A2B receptor -/- with zymosan vs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 10432 ± 1099vs. 10337 ± 2293 | P=nsn=12/10 |
| Macrophage-inflammatory protein-2: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 2225 ± 817vs. 1008 ± 458 | P=0.006n=8/11 |
| Macrophage-inflammatory protein-2:adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 3064 ± 778vs. 2570 ± 997 | P=nsn=10/12 |
| Tumor necrosis factor α: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 523 ± 227vs. 281 ± 101 | P=0.002n=9/9 |
| Tumor necrosis factor α: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 386 ± 138vs. 335 ± 86 | P=nsn=13/11 |
| Interleukin-6: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 35.7 ± 16.4vs. 23.9 ± 6.8 | P=0.004n=14/12 |
| Interleukin-6: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 31.0 ± 12.1vs. 28.7 ± 6.7 | P=nsn=12/15 |

|  |  |  |
| --- | --- | --- |
| **Table 2E** | **Neutrophils (x105)** | ***P* values; n counts** |
| Lavage: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | median [25%, 75%]: 4.9 [3.5, 7.1] x105 vs. 3.0 [1.9, 3.5] x105 | P=0.010n=8/8 |
| Liver: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 16.1 ± 3.7 x105vs. 8.9 ± 3.4 x105 | P<0.001n=8/8 |
| Lung: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 57.1 ± 9.1vs. 40.8 ± 15.9 | P=0.037n=8/8 |

|  |  |  |
| --- | --- | --- |
| **Table 2F Myeloperoxidase** | **[405nm/ml]** | ***P* value; n counts** |
| Wild-type with zymosanvs. wild-type with zymosan and sevoflurane | median [25%, 75%]: 2.6 x 105 [2.3 x 105, 2.7 x 105] vs. 2.0 x105 [1.5x105, 2.2x105] | P<0.001n=11/8 |

|  |  |  |
| --- | --- | --- |
| **Table 2G Protein** | **[mg/ml]** | ***P* value; n counts** |
| Wild-type with zymosanvs. wild-type with zymosan and sevoflurane | median [25%, 75%]: 3.4 [3.2, 3.4] vs. 2.8 [1.5, 3.1] | P<0.001n=8/8 |